Furthermore, we found the mutations of STAG2 (Fisher’s exact test, p = 1.1E–3, track 2 vs. track 4 vs. track 5 vs track 6 = 0% vs. 0% vs. 30.4% vs. 0%) and USP6 (Fisher’s exact test, p = 3.1E–3, track 2 vs. track 4 vs. track 5 vs track 6 = 0% vs. 0% vs. 26.1% vs. 0%) were prominent in track 5, which were all co-occurrence with AKAP9 mutation (Fisher’s exact test, p = 3.2E–5 for STAG2 and 9.3E–6 for USP6), suggesting the roles of glycolysis in the ESCC patients in track 5 (Fig. 6d). This evidence concerns the gene STAG2 and esophageal squamous cell carcinoma.